SI
NBIX icon

Seeds Investor’s Neurocrine Biosciences NBIX Stock Holding History

Seeds Investor’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$411K Sell
2,437
-27
-1% -$4.01K 0.04% 247
2026
Q1 		$322K Sell
2,464
-30
-1% -$3.98K 0.04% 262
2025
Q4 		$354K Buy
2,494
+233
+10% +$33.8K 0.07% 172
2025
Q3 		$317K Buy
2,261
+449
+25% +$60.8K 0.07% 173
2025
Q2 		$228K Buy
+1,812
New +$208K 0.05% 215
2024
Q2 		– Sell
-1,691
Closed -$233K – 223
2024
Q1 		$233K Buy
+1,691
New +$231K 0.21% 137

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Seeds Investor's NBIX Position: Q2 2026 in Review

Seeds Investor reduced its Neurocrine Biosciences (NBIX) stake by 1.1% in Q2 2026, selling an estimated $4.01K and leaving 2,437 shares worth $411K. The position accounts for 0.04% of the portfolio, ranked #247.

Seeds Investor first reported a position in NBIX in Q1 2024 and has held it in 6 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Seeds Investor held 2,437 shares of Neurocrine Biosciences worth $411K as of Q2 2026.
  • Seeds Investor sold 27 Neurocrine Biosciences shares in Q2 2026, an estimated $4.01K.
  • Neurocrine Biosciences made up 0.04% of Seeds Investor's portfolio in Q2 2026, its #247 holding.
  • Seeds Investor first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 6 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Seeds Investor's 13F filing for Q2 2026, filed 12 Aug 2026.